BioSpace News Archive

Artax Biopharma, Inc. announces important changes and expansions to its Executive Team as the Company enters its critical next phase.

Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, highlighted recent progress across the company’s cell and gene therapy portfolio and provided updates on anticipated upcoming milestones.

Resalis Therapeutics announced the closing of a €10 million Series A financing round led by Sunstone Life Science Ventures with participation from existing investors including Claris Ventures and angel investors.

Tryp Therapeutics Inc. is pleased to announce that the first patient has been dosed in a Phase 2a clinical trial being conducted by the University of Michigan in a collaboration with Tryp Therapeutics.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that the investigational CT-155 prescription digital therapeutic (PDT), co-developed by Boehringer Ingelheim and Click Therapeutics, has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

Scinai Immunotherapeutics Ltd. today published a letter from its CEO, Amir Reichman, addressing the Company’s 2023 accomplishments.

During 2023, we took a number of decisive actions to help position the Company for success in 2024 and beyond. We prioritized our pipeline, strengthened our organization and implemented a disciplined capital allocation model to generate cost efficiencies.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and product-specific J-code (J3401) for VYJUVEK® (beremagene geperpavec-svdt), the first U.S. Food and Drug Administration-approved treatment for dystrophic epidermolysis bullosa (DEB).

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced its 2024 clinical pipeline plans and highlighted recent corporate achievements.

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) today announced that the Company will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11 at 9:00 am PST (12:00 pm EST).